Key result
Colchicine substantially decreased IL-6 levels and improved left atrial reservoir strain and functional class compared to placebo at 6 months in patients with chronic rheumatic mitral valve disease.
Why the study?
Does colchicine reduce systemic inflammation and improve left atrial mechanical function in patients with chronic moderate to severe rheumatic mitral valve disease?
Does colchicine reduce systemic inflammation and improve left atrial mechanical function in patients with chronic moderate to severe rheumatic mitral valve disease?
Answers are grounded in this paper and cite their sources.
Colchicine shows promise as a disease-modifying therapy for chronic rheumatic heart disease by reducing inflammation and improving atrial function, warranting larger definitive trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Un et al. (2026) conducted an editorial in Chronic moderate to severe rheumatic mitral valve disease. Colchicine vs. Placebo was evaluated on Change in IL-6 at 6 months. Colchicine substantially decreased IL-6 levels and improved left atrial reservoir strain and functional class compared to placebo at 6 months in patients with chronic rheumatic mitral valve disease.
Synapse has enriched 10 related papers. Consider them for comparative context: